Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04800614 · ClinicalTrials.gov registry record · Phase 1
A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib
A Phase 1 study of Healthy Adults, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT04800614: Completed Phase 1 study of Healthy Adults, sponsored by Mirati Therapeutics.
NCT04800614 is a Phase 1 study of Healthy Adults that has completed, run by Mirati Therapeutics. The registered enrollment target is 36 participants, below the 85-participant average among 33 other Healthy Adults trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04800614, a Phase 1 study of Healthy Adults, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
An Open-label, Randomized, Three-period, Crossover Study of the Effect of Food on the Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects
Primary Outcome
Maximum observed plasma concentration
Conditions Studied
Interventions
- DRUG sitravatinib
Study Locations (1)
Texas
- Covance Clinical Research Unit, Inc. - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-03-15 |
| Est. Completion | 2022-03-28 |
| Phase | Phase 1 |
What the finished NCT04800614 record still lists
NCT04800614 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 85-participant average among 33 other Healthy Adults trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Healthy Adults appearing as the primary indexed condition, and to 1 intervention - of which sitravatinib is the first listed.
NCT04800614 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04800614 about?
NCT04800614 is a clinical study titled "A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib". An Open-label, Randomized, Three-period, Crossover Study of the Effect of Food on the Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects
What is the current status of trial NCT04800614?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2021-03-15. Estimated completion is 2022-03-28.
What conditions does trial NCT04800614 study?
This clinical trial studies the following conditions: Healthy Adults.
What interventions are being tested in trial NCT04800614?
The interventions under investigation include: sitravatinib (DRUG).
Who is sponsoring clinical trial NCT04800614?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04800614 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adults
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04800614's enrollment target sits among peer trials
36 18th of 33 higher than 16 of 33 other Healthy Adults trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Adults trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of EDG-15400 in Healthy Adults
RECRUITING · Phase 1
-
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
RECRUITING · Phase 1
-
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults
RECRUITING · Phase 1
-
Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans
RECRUITING · Phase 1
-
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors
RECRUITING · Phase 1
-
The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI